OL-101

OL-101 is an innovative autologous CAR-T cell therapy designed to target multiple myeloma, particularly for patients with relapsed or refractory disease. This dual-targeting therapy focuses on both BCMA (B-cell maturation antigen) and GPRC5D (G-protein coupled receptor family C group 5 member D), which are important targets in multiple myeloma treatment. ## Development Status OL-101 is currently in Phase 1 clinical development. A clinical trial (NCT06644118) began recruiting patients in October 2024 in China, sponsored by Zhejiang University in collaboration with Allogene Overland Therapeutics[1][2]. This trial aims to establish the safety profile and recommended dosage for future research, as well as evaluate the efficacy of OL-101 in patients with relapsed or refractory multiple myeloma (RRMM). ## Mechanism of Action The therapy works through a dual-targeting approach, modulating both BCMA and GPRC5D receptors[1]. This dual-targeting strategy is particularly significant as it may address the challenge of post-BCMA relapse in multiple myeloma patients, potentially offering a more comprehensive treatment approach. ## Administration OL-101 is administered intravenously, which is typical for CAR-T cell therapies[2]. The treatment involves collecting a patient's own T cells, genetically modifying them to target specific cancer markers, and then reinfusing them back into the patient. ## Development Timeline According to available information, OL-101 was on track for human clinical testing in the fourth quarter of 2024[2], which aligns with the October 2024 start date of the current Phase 1 trial. The therapy is being developed with the potential to eventually move into earlier lines of therapy for multiple myeloma patients. ## Organizations Involved The development of OL-101 involves Allogene Overland Therapeutics (PRC) Co., Ltd. as the originator organization, with active involvement from both Allogene Overland Therapeutics and Zhejiang University in the ongoing clinical trials[1][2].